Home/Filings/4/0001209191-18-002054
4//SEC Filing

Gulino Richard L. 4

Accession 0001209191-18-002054

CIK 0001347178other

Filed

Jan 3, 7:00 PM ET

Accepted

Jan 4, 5:11 PM ET

Size

14.4 KB

Accession

0001209191-18-002054

Insider Transaction Report

Form 4
Period: 2018-01-02
Gulino Richard L.
SVP & General Counsel
Transactions
  • Exercise/Conversion

    Restricted Stock Unit

    2018-01-027,50015,000 total
    Common Stock (7,500 underlying)
  • Exercise/Conversion

    Common Stock

    2018-01-02+12,50076,600 total
  • Exercise/Conversion

    Restricted Stock Unit

    2018-01-0212,50025,000 total
    Common Stock (12,500 underlying)
  • Exercise/Conversion

    Common Stock

    2018-01-02+7,50099,100 total
  • Sale

    Common Stock

    2018-01-02$15.20/sh10,367$157,56588,733 total
Footnotes (8)
  • [F1]Each Restricted Stock Unit ("RSU") was previously reported on Table II on a Form 4 filed with the Securities and Exchange Commission ("SEC") on September 15, 2015.
  • [F2]Each RSU represents a contingent right to receive a share of the Issuer's Common Stock.
  • [F3]Starting with the January 2, 2018 vesting of the RSUs, the Issuer's method of reporting RSUs has been revised to report such grants in Table I rather than as previously reported in Table II. Accordingly, the share numbers reported in Column 5 of Table I includes unvested RSUs previously reported in Table II.
  • [F4]Each RSU was previously reported on Table II on a Form 4 filed with the SEC on February 17, 2016.
  • [F5]Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs as reflected in this Form 4. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors.
  • [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.15 to $15.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (6) to this Form 4.
  • [F7]The RSUs vest in four (4) equal annual installments beginning January 1, 2017, provided Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest.
  • [F8]Not Applicable.

Issuer

Vanda Pharmaceuticals Inc.

CIK 0001347178

Entity typeother

Related Parties

1
  • filerCIK 0001652208

Filing Metadata

Form type
4
Filed
Jan 3, 7:00 PM ET
Accepted
Jan 4, 5:11 PM ET
Size
14.4 KB